now you can see mylan up by 2%. three analysts said maybe this isn't a big deal there are other things driving the stock up. it's been climbing over the last week ahead of several catalysts including an analyst day march 1st and couple of fda decisions on generic drugs. a lot going on with mylan as you can see. >> meg was talking about some other things. on the halftime show today pointed to some bullish options buying in the most recent days. this specifically was one of the stocks he highlighted. technically mylan is set up to do fairly well in the short term. >> i was surprised that this kind of news would send the stock up instead of down. there's a worry bag that analysts have around this stock and this is one item that gets out of that. >> reporter: i was asking a lot of folks about this. they said it wasn't that big of a story for mylan. it isn't a small amount of money but to mylan what's driving the shares is anticipation of decision from the fda. interesting scott was saying that. one analyst said you can'

remember, mylan went after perrigo. 75% share in cash. 2.51 shares of mylan.errigo should have taken that team. mylan should have taken that deal. the only one that came out well was allergan, which teva would pay $40 billion for the generics business of. the deal took forever to get done, given a longer regulatory review than people anticipated. during the period, the market for generics changed. teva had all sorts of debt. now, they're looking at that debt load, trying to figure out how to restructure it to a certain extent. some asset sales may take place at the company. they produce a lot of cash flow so there is no danger in the larger context for teva. they do want to restructure a debt. so back to today's announcement there. let's not forget perrigo, that star board wins basically a nice settlement. jeff smith, who runs star board, the activist fund you may remember from the battles taking place at yahoo! he'll step on to the board along with two other members. including, did you see jeff kinler, former ceo of pfizer, he'll be on the board. they have pl

>> i like the mylan idea, john. >> wow!multi-year bottom formed here, inverse head and shoulders bottom. stock now breaking out from the neckline. meanwhile you have a positive divergence in rsi. on the way down september, october, november, the selling had been slowing down the whole time. now you have an rsi 65. bulls are coming into this thing on the way up. >> yes! >> exactly what i want to say. >> jimmy, give me ten seconds. >> he wants ten seconds, mylan. >> i'm not going to fight the tape. i never fight the tape. >> that a boy. >>> we'll take a quick break and come back to do some final trades. the guys will make their way back to the desk. whkingballos $ atuecata what'sm w?(cs) att wort talk tom? what's'sno wlth,buthint t tter t t >>> we are back. we want to remind you once again tomorrow, 12:00 pm eastern, cnbc exclusive interview with kevin plank, ceo of under armour. plenty to talk about. can't wait to catch up with kevin plank tomorrow at the new york stock exchange. >>> markets close in three hours. time for fi

mylan you are always welcome on the show. i will be fair with you but you've got to come on, we have so many viewers suffering from this and need your product. >>> let's get to it, just under three hours and counting for the deadline of the trump administration to submit documents to the ninth u.s. circuit court of appeals to justify president trump's executive order on the travel ban. remember, another judge said stop, he can't do it, and now it's the department from, of course, donald trump's team that has to present at 6:00 p.m. eastern, now that's 2 hours and 56 minutes away, why that should be overturned and get back into action, something far more powerful than a ticking clock might hit the administration square in the forehead. a supreme court showdown. that's what my next guest thinks, former ambassador for mideast policy, ambassador marc ginsberg. okay, ambassador, going all the way to the supreme court? how fast does that kind of thing happen? >> it's on a fast track to go nowhere. let's be very honest about this, d

verma: i think what happened with the mylan pen and epipen issue is very disturbing. the idea that perhaps medicaid programs, which are struggling to pay for those programs, that they could have potentially received rebates is disturbing to me. so film' confirmed, i would like to review the processes in place there in terms of the classifications. in terms of brand and generic to ensure at that type of thing doesn't happen again. senator grassley: what you just said you want to do i want to do. that's why i want those communication from c.m.s. i hope you'll get them for me. ms. verma: i hope you'll -- i'll be happy to get that to you. senator stabenow: first thing, many questions i have. first regarding medicare. do you believe that medicare programs should negotiate the best price for seniors on medicare? ms. verma: i think we need to do everything that we can do to make drugs more affordable for seniors. i'm thankful that we have the b.m. -- p.b.m.'s and the part d programs that are performing that negotiation. senator stabenow: do you believe we could get a better

i saw your interview with mylan. it doesn't make sense.making that determination. our job, quite frankly, to the extent they've been inflating them, to go and make sure our clients don't pay the high price. >> just answer this question the price of drugs go up, does the rebate you receive also go up? predetermined by the clients. >> to gayle's point as i'm sitting here watching this right now it does seem as though, there's fingers being pointed back and forth. and i'm forced to decide who the bad guy is? >> and i understand that, but what i say is when you look at what we do and the results we got. again, our report yesterday showed it may not be simple. i'm not going to sit here and tell you it's a simple process, but we get results. >> could you make public the amount pbms received in rebates? cow make that more transparent, so that the consumer, the patient ask understand the supply chains, who is getting a cut of every piece of drug, would you support that? >> we support absolute transparency with our client. and we support as well tr

in 2016, mylan pharmaceuticals ceo was grilled by congress when her company raised the price of the epipenug prices work in the u.s. versus the red of the world. in europe, governments negotiate to limit what their state health systems paid. company set whatever price the market will bear. while medicare legally can't negotiate drug prices, private insurers can. private payers typically ride rely on -- to negotiate discounts. bm's often make deals with insurance makers. in the income americans wind up paying 17% out-of-pocket. pharmaceutical companies say that high profits are necessary to fund research and development, and that regulating drug prices might slow medical advances. advocates say lower prices would not stop innovation and point out some drug companies spend more on marketing than research and development. that was just one of the many quick takes you can find him a bloomberg. you can also find them at bloomberg.com with the latest business news and analysis 24 hours a day. that is all for "bloomberg best" this week. thank you for watching. i'm alix steel. this is bloomberg. ♪

i saw your interview with mylan and i heard the explanation.use at the end of the day, you know from a standpoint of drug prices, pharma companies are making that determination. our job is, quite frankly, to the extent that they've been inflating them, to make sure our clients don't pay those higher prices. >> just this question, when the price of drugs goes up, does the rebate you receive also go up? >> not always, but when it does, it flows through to our clients, as we've predetermined with our clients. >> to gayle's point here, watching this now, it does seem as though they're just fingers being pointed back and forth, and i'm forced to decide who the bad guy is. >> that's -- and i understand that. but what i'd say is when you look at what we do and the results we got -- again, our report yesterday shows that it may not be simple. i'm not going to sit here and tell you it's a simple process, but we get results. >> could you make public the amount pbms receive in rebates? could you make that more transparent so that the consumer, the patient

>> i think what happened with the mylan and the epipen issue is very disturbing. the idea that perhaps medicaid programs, which are struggling to pay for those programs, that they could have potentially receive rebates is disturbing to me. so if i'm confirmed i would like to review the process in place there in terms of the classification. in terms of brand and generics to ensure that type of thing doesn't happen again. >> what you just said you want to do, i want to do and that's why i want this communication from cms, i hope you can get them. >> i'll be happy to work with you on that. >> center 70. >> that you very much and welcome to you and your family. the first thing, many many questions i have but first regarding medicare, you believe that medicare programs should negotiate the best price for seniors on medicare? >> i think that we need to do everything we can do to make drugs more affordable for seniors. and i'm thankful that we have the pbn's and part d programs that are performing that negotiation on behalf of seniors. >> you believe we could get a bette

pharma and some of the generic drug companies, the two biggest generic drug companies are teva and mylanproblems there. teva ceo just that down. -- stepped down. my land and their ip pram -- heir epipen drugat th gouging. to pay up for that compensation, they are gouging the public. know you do. bruce: reach out to the congress and the president and the fda because the system needs to be fixed. it is truly broken. that's one of the key reasons why the united states, who has got the best research, the best drug companies, has the highest drug prices in the world by a multitude beyond any other country. vonnie: let's move on to other promises this administration has made. in the area of deregulation and tax policy, there could be a potential whole shift in the market. bruce: specifically what would you like me to comment on? vonnie: let's talk about tax reform. bruce: on tax reform specifically, the reform is multifaceted. it is to lower the corporate tax rate from 35% where it is now. speaker ryan once 20%. donald trump and the in ministratio -- and the administration wants 15%. that's pr

buying 5 million shares on teva and 5 million in pfizer and 3 million in mylan and allergen each. they like bank of america. we saw more capital, tiger management and third point all adding more than a million shares each in b of a. they took stake in citigroup and jpmorgan. these are the first stakes taken since the election. tech was also an interesting play this quarter as berkshire hathaway tripled its position in apple but other hedge funds were less optimistic on the sector. tepper cut his stake in apple in half. we saw other sales in amazon, facebook, alibaba was another stock that experienced some selling. back to you guys. >>> president trump's sons eric and donald jr., they'll be heading to dubai for the opening of a brand-new trump golf resort built by the uae based properties. the golf club dubai has drawn criticism that it creates a conflict of interest with critics that say president trump isn't distancing himself from the business. >>> tourism development authority is joining us. a lot of people are looking at what's taking place in the u.s. and they're looking at t

have involved makers of generic drugs, valeant raising the price on two older heart medications and mylan the biggest makers of generic medicines. the whole industry is under fire for practices, new campaign emphasizing the cost savings they bring to the system, the slogan keeping medicines within reach. a name change now the association for accessible medicines. its message? generic drugs are about 90% of all prescriptions filled in the u.s. each year but account for a quarter of drug costs. and brand drugs could threaten much cheaper alternatives. trump met with branded pharmaceutical companies and trade group pharma a couple of weeks ago after pharma rolled out its own campaign. the message from generic drugmakers today, don't lump us all in together. brian? >>> chip davis, ceo of the new ly rebranded association for accessible medicines, the group representing the generic drugmakers. chip, thank you very much for joining us. you heard meg's excellent report. where do we stand? where is the proper balance between making sure that the companies who spend and create these drugs have the

bought new stakes in pfizer and mylan and upped allergen and cut apple. >>> nelson peltz's fund has takenke in procter & gamble. it's roughly $3.5 billion. the move is a sign that they're taking aim at the consumer product giant's increase in sales and gets rid of the unprofitable brands. trian makes it another month to trying to invest. p&g reacted well to the news yesterday, up 2.7%. >> that's right. csx wants shareholders to vote on the demands an activist investor is making there as it tries to install the former ceo of canadian pacific of the head of the railroads. csx will call a meeting. they say they hold a nearly 5% stake in csx and wants to introduce the model harrison hunter used. they want excessive compensation and enough board seats to effectively control the company. that's an interesting fight that's going on at that company. >>> meantime, president trump will meet with the ceos of eight large u.s. retailers this morning. they're expected to discuss tax reform and making improvements to infrastructure. the group will include target ceo and gap ceo and jcpenney ceo. the ret

and he also gained new positions in testiva, pfizer and mylan. >> did he say anything about the timingses and whether or not the elections played a role. >> he wouldn't comment on that, but other hedge fund managers didn't want to touch pharmaceuticals because of the election. >> did he also say he's going to move back to new jersey and help fill the budget gap he created when he moved for florida. >>> meg tirrell, we want your take on tepper, but you've been tracking movers. >> huge movesers, this is a new gene edited technology named crisper. there's a patent case going on affecting three stocks. you can see these are all swinging wildly on the results of a uspto decision in that case in favorite of editas. it's up more than 20%, the competitors almost down as much. they ruled in favor of this patent that editas holds. however, this may not signal the end. there could be appeals or other things, but big november in these names, guys. are these biotech specialists? i'm just could you yurt who would know enough to be taking bets in this. >> pretty small name -- so probably a lot of bio

all the media attention focused in the past year has been on cases like mylan, cases talking about oldgs where there is not effective competition so we think there are targeted solutions to those problems. you could have more resources dedicated to reducing the backlog with regard to generic approval. you can have manufacturing and tax incentives put in place to encourage generic entry. let's look at targeted solutions that address the problem. lauren: we know about the case of the epipen and associated to that, offering tiered pricing especially for schools and the like but it is still an expensive process. is your fear the balance we got to find, the money farm a pays to get a drug to market or and epipen to market has to be balanced out with humanitarian needs to provide support? >> absolutely. one of the other steps we need to take it increasingly our companies want to engage directly with payers and put the money where their mouth is and reimburse differentially based on the outcome achieved by the patients. instead of one price for one pill, a more granular discussion with payers

as importantly, there is another, and this came up a lot when mylan was fighting off schticting. it controls a lot of parts of the company. you have a netherlands part and anglo part. if you want to buy the nv part you have to go through the trust. now they will vote their shares according to the way their depository shareholders want them to, but they have an important role here. again, it is another potential impediment to making a deal more difficult were kraft/heinz to want to go directly to shareholders over objections of the board. >> sara, you know about these companies. do they raise the price to something more appealing to unilever here? >> that's one possibility. schticting and booby prizes aside. the context is interesting. as someone who covers these companies, everyone expected heinz, craft hindes and 3g, the private equity firm run by brazilians, to make the deal. everyone expected that in the food base. unilever is only half food business. it's more than half consumer products, shampoos, axe deodorants, dove soaps. this would be the first foray into that area. it's

lab in beltsville maryland mylan created the largest diamond d every grown in the united t states. >>ore than six carrots. the federal trade commissionommo says the diamond is chemicallyly and physically identical to an earth mined diamond and a synthetic diamonds of course are cheaper. 1 carat earth diamond costs morr than five grand. one carrot diamond grown in itst lab costs 2600 bucks. buc so this is the question.ueio like would you propose with onet of these earth diamonds like not an earth diamond but a lab diamond. >> you can tell the difference. >> what's the answer?the aner? >> me personally?soll >> yeah.h >> i don't think so. >> okay. >> i think that's smart.hihat' >> unless you say this is a thi diamond mined in a lab.ab. >> it's beautiful and it's a lot less expensive does looking atoi stones together and that was okay. do itetheas up.p. >> just asking.in. >> wait a little bit. wait >> on this valentine's day weens want to see some of your love lv stories today if you have a special valentine in your liferi give them a shout out use the t #fox5lovestory. we're getting grea

his firm appaloosa took advantage of a dip in pharma to buy names such as teva, mylan and pfizer.s excited about allergan. it now represents more than double his other pharma positions combined he said. >> who's not bullish on allergan? that's the question. >> well, it dipped in the fourth quarter of the year and it's a little uncertain. >> isn't it botox? >> i think it's body con touring. >> who's botox? >> that's botox but body con touring has become the new -- >> they're both important to some people. i mean, i'm not -- >> some people? >> yeah, the needle in the, you know, forehead is a deal breaker for me but -- have you tried that? actually, you have. i can tell you have. >> missed that opportunity. >> you still smile and you have good expressions. thank you. this is you. >> thank you very much, lessee. appreciate it. >>> programming note for the -- by the way, folks, we're going to be sitting down with warren buffet on february 27th for the annual ask warren show. he wouldn't comment on any of these moves last night when i spoke with him. he says he's not going to be talking